For further details see:
RIOT, MARA, SOS among premarket gainersFor further details see:
RIOT, MARA, SOS among premarket gainersMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potentia...
Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH...